Sangamo Therapeutics Inc GBY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.48
- Day Range
- $0.55–0.55
- 52-Week Range
- $0.24–—
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $114.13 Mil
- Volume/Avg
- 4,500 / 295
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.65
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 405
- Website
- https://www.sangamo.com
Comparables
Valuation
|
Metric
|
GBY
|
AKBA
|
BIVI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.13 | — | 1.48 |
Price/Sales | 5.65 | 1.10 | — |
Price/Cash Flow | — | 30.47 | — |
Price/Earnings
GBY
AKBA
BIVI
Financial Strength
|
Metric
|
GBY
|
AKBA
|
BIVI
|
|---|---|---|---|
Quick Ratio | 1.37 | 1.03 | 2.43 |
Current Ratio | 1.71 | 1.70 | 2.45 |
Interest Coverage | — | −5.18 | −9.50 |
Quick Ratio
GBY
AKBA
BIVI
Profitability
|
Metric
|
GBY
|
AKBA
|
BIVI
|
|---|---|---|---|
Return on Assets (Normalized) | −80.71% | −13.51% | −115.58% |
Return on Equity (Normalized) | −122.41% | — | −256.00% |
Return on Invested Capital (Normalized) | −106.07% | −86.71% | −130.07% |
Return on Assets
GBY
AKBA
BIVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ghcffxpbw | Ckxpznk | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rbhcwhs | Zprnbr | $114.2 Bil | |||
| Moderna Inc
MRNA
| Grbdknlj | Rhvm | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Kjysldct | Yzmm | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Sxfthgsf | Nslhj | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lhhyflj | Qdqqj | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vnypvffb | Ktcvjld | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Tgxqvbchy | Qlvl | $12.8 Bil | |||
| Incyte Corp
INCY
| Yklyfjm | Vnxdq | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Hgbzljtfm | Yjtzxf | $12.2 Bil |